Triple
T17871417
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Alnylam Pharmaceuticals, Inc. |
E446844
|
entity |
| Predicate | develops |
P73
|
FINISHED |
| Object | OXLUMO (lumasiran) |
—
|
NE NERFINISHED |
How this triple was built (3 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: OXLUMO (lumasiran) | Statement: [Alnylam Pharmaceuticals, Inc., develops, OXLUMO (lumasiran)]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: OXLUMO (lumasiran) Context triple: [Alnylam Pharmaceuticals, Inc., develops, OXLUMO (lumasiran)]
-
A.
Evrysdi
Evrysdi is an oral prescription medication used to treat spinal muscular atrophy (SMA) by increasing production of the survival motor neuron (SMN) protein.
-
B.
Onpattro
Onpattro is an RNA interference (RNAi) therapeutic used to treat polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis.
-
C.
Alecensa
Alecensa is a targeted cancer therapy (alectinib) primarily used to treat ALK-positive non-small cell lung cancer.
-
D.
Talycopa
Talycopa is a locality or area within the community of Llansamlet in Swansea, Wales.
-
E.
Iclusig
Iclusig is a cancer medication containing ponatinib, primarily used to treat certain types of leukemia such as chronic myeloid leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL).
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: OXLUMO (lumasiran) Target entity description: OXLUMO (lumasiran) is an RNA interference–based therapeutic used to reduce elevated oxalate levels in patients with primary hyperoxaluria type 1.
-
A.
Evrysdi
Evrysdi is an oral prescription medication used to treat spinal muscular atrophy (SMA) by increasing production of the survival motor neuron (SMN) protein.
-
B.
Onpattro
Onpattro is an RNA interference (RNAi) therapeutic used to treat polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis.
-
C.
Alecensa
Alecensa is a targeted cancer therapy (alectinib) primarily used to treat ALK-positive non-small cell lung cancer.
-
D.
Talycopa
Talycopa is a locality or area within the community of Llansamlet in Swansea, Wales.
-
E.
Iclusig
Iclusig is a cancer medication containing ponatinib, primarily used to treat certain types of leukemia such as chronic myeloid leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL).
- F. None of above. chosen
Provenance (2 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69d8b9f4c22c819093c2680434472894 |
completed | April 10, 2026, 8:51 a.m. |
| NER | Named-entity recognition | batch_69e49aa30ff8819090c51c1d7767e952 |
completed | April 19, 2026, 9:04 a.m. |
Created at: April 10, 2026, 10:18 a.m.